Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Cancer Letters · 2025-02 · 610 · 217350
DOI: 10.1016/j.canlet.2024.217350 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-02. Verfasst von Baofa Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Taimei Baofa Cancer Hospital, Dongping, Shandong, 271500, China; Jinan Baofa Cancer Hospital, Jinan, Shandong, 250000, China; Beijing Baofa Cancer Ho…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Biomarkers, Tumor, Immunotherapy. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic cancer remains one of the most challenging malignancies to treat due to its late-stage diagnosis, aggressive progression, and high resistance to existing therapies. This review examines the latest advancements in early detection, and therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, and the integration of artificial intelligence (AI) in data analysis. We highlight promising biomarkers, including microRNAs (miRNAs) and circulating tumor DNA (ctDNA), that offer enhanced sensitivity and specificity for early-stage diagnosis when combined with multi-omics panels. A detailed analysis of the TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, and the extracellular matrix (ECM) contribute to therapy resistance by creating immunosuppressive barriers. We also discuss therapeutic interventions that target these TME components, aiming to improve drug delivery and overcome immune evasion. Furthermore, AI-driven analyses are explored for their potential to interpret complex multi-omics data, enabling personalized treatment strategies and real-time monitoring of treatment response. We conclude by identifying key areas for future research, including the clinical validation of biomarkers, regulatory frameworks for AI applications, and equitable access to innovative therapies. This comprehensive approach underscores the need for integrated, personalized strategies to improve outcomes in pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Taimei Baofa Cancer Hospital, Dongping, Shandong, 271500, China; Jinan Baofa Cancer Hospital, Jinan, Shandong, 250000, China; Beijing Baofa Cancer Hospital, Beijing, 100010, China; Immune Oncology Systems, Inc, San Dieg…
- Institute of Microbiology and Immunology, Huzhou University School of Medicine, Huzhou, Zhejiang, 313000, China. Electronic address: sswhit@163.com.
- Department of Medicine, Sanford Stem Cell Institute, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. Electronic address: wma@health.ucsd.edu.
Zitieren
APA
Yu, B., Shao, S., & Ma, W. (2025). Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy. Cancer Letters, 610, 217350. https://doi.org/10.1016/j.canlet.2024.217350
Vancouver
Yu B, Shao S, Ma W. Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy. Cancer Letters. 2025;610:217350. doi:10.1016/j.canlet.2024.217350
BibTeX
@article{Yu2025,
author = {Yu, Baofa and Shao, Shengwen and Ma, Wenxue},
title = {Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy},
journal = {Cancer Letters},
year = {2025},
volume = {610},
pages = {217350},
doi = {10.1016/j.canlet.2024.217350}
}
EUVIMED